Skip to content

Pilot Studies Blocking Injury-Induced MVP Release in Skin Using Topical Amitriptyline

Pilot Studies Blocking Injury-Induced MVP Release in Skin Using Topical Amitriptyline

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07716722
Enrollment
50
Registered
2026-07-21
Start date
2026-07-01
Completion date
2032-07-01
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amitriptyline, Thermal Burn

Brief summary

The purpose of this study is to determine the amount of substances contained in skin known as microvesicle particles (MVP). Studies suggest these MVP are involved in many conditions such as after the thermal burn injury. These particles are typically found in skin and are evaluated by taking a portion of area with skin biopsy. The hypothesis to be tested is that people treated with a small burn injury will result in MVP levels and that this can be blocked by applying the drug amitriptyline to the area. The topical amitriptyline will be given either immediately after the burn, or at a short time afterwards (5 or 15 minutes). Skin biopsies of the areas will be taken and the study team will measure the MVPs in the skin. By utilizing these methods the study team can determine if there are differences in the numbers of MVP made following a small thermal burn injury and if this can be blocked by topical treatment with amitriptyline.

Interventions

DRUGAmitriptyline

10% amitriptyline

OTHERPlacebo

Placebo

Sponsors

Wright State University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult Males/Females ages 18-64 * All skin types on Fitzpatrick Scale (Type I-VI) * Able to comprehend procedures and risks * Must be able to give informed consent

Exclusion criteria

* Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus) * History of abnormal scarring (i.e., keloids) or poor wound healing * No over the counter non-steroidal anti-inflammatory agents (aspirin, acetaminophen) or antioxidant vitamins (vitamin C) in past 14 days. * Currently taking known photosensitizers, anti-inflammatories, other tricyclic antidepressants, or systemic agents known to be ASM inhibitors * Large tattoos in designated testing areas * Tanning bed use within last 3 months * UVB treatments in past 3 months * Pregnant or nursing * Known allergies to lidocaine or amitriptyline

Design outcomes

Primary

MeasureTime frameDescription
Change in the amount of microvesicle particles generated in skin from localized thermal burn injury over untreated skin.2 hours after the burn injuryAnesthetized volar forearm skin will be treated with a heated 3.5 mm metal rod to generate a thermal burn injury. Immediately after the burn injury 0.1mL of polyethylene glycol vehicle will be applied. Vehicle will also be applied to nearby un-burned skin. Skin biopsies of burned provided vehicle and nearby unburned area with vehicle will be obtained 2 hours after localized burn injury. MVP will be measured. Briefly, the biopsies will be weighed, and treated with enzymes to break down the tissue. Following several centrifugation steps, the MVP fraction will be measured using a Nanosight instrument. The MVPs will be normalized to biopsy weight. The numbers of MVP in untreated skin will be compared to skin which underwent a thermal burn injury.

Secondary

MeasureTime frameDescription
The amount of MVP released after topical 10% amitriptyline is provided immediately after localized thermal burn injury compared to vehicle.2 hours after the burn injuryAnesthetized volar forearm skin will be treated with a heated 3.5 mm metal rod to generate a thermal burn injury. Immediately after the burn injury 0.1mL of polyethylene glycol vehicle will be applied to one burned area and 10% amitriptyline will be applied to the other burned site. Skin biopsies of burned provided and nearby untreated area will be obtained 2 hours after localized burn injury. MVP will be measured. The biopsies will be weighed, and treated with enzymes to break down the tissue. Following several centrifugation steps, the MVP fraction will be measured using a Nanosight instrument. The MVPs will be normalized to biopsy weight. The numbers of MVP in skin treated with vehicle + burn injury will be compared to skin treated with amitriptyline + burn injury to ascertain if the amitriptyline can decrease the burn-induced MVP release.

Countries

United States

Contacts

CONTACTPharmacology Translational Unit
pturesearch@docdermgroup.com937-245-7500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026